These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37254958)

  • 41. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.
    Youssif BGM; Abdelrahman MH; Abdelazeem AH; Abdelgawad MA; Ibrahim HM; Salem OIA; Mohamed MFA; Treambleau L; Bukhari SNA
    Eur J Med Chem; 2018 Feb; 146():260-273. PubMed ID: 29407956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers.
    Elzahabi HSA; Nossier ES; Alasfoury RA; El-Manawaty M; Sayed SM; Elkaeed EB; Metwaly AM; Hagras M; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1053-1076. PubMed ID: 35821615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of new 1
    Gaber AA; Sobhy M; Turky A; Abdulwahab HG; Al-Karmalawy AA; Elhendawy MA; Radwan MM; Elkaeed EB; Ibrahim IM; Elzahabi HSA; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2283-2303. PubMed ID: 36000168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis, molecular docking of new lipophilic acetamide derivatives affording potential anticancer and antimicrobial agents.
    Ahmed HEA; Ihmaid SK; Omar AM; Shehata AM; Rateb HS; Zayed MF; Ahmed S; Elaasser MM
    Bioorg Chem; 2018 Feb; 76():332-342. PubMed ID: 29227917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
    Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
    Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
    Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.
    Deshmukh TR; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Shingate BB
    Bioorg Med Chem Lett; 2019 Oct; 29(19):126618. PubMed ID: 31431361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
    Sobh EA; Khalil NA; Faggal SI; Hassan MSA
    Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
    Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
    Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition.
    Amin MM; Abuo-Rahma GEA; Shaykoon MSA; Marzouk AA; Abourehab MAS; Saraya RE; Badr M; Sayed AM; Beshr EAM
    Bioorg Chem; 2023 May; 134():106444. PubMed ID: 36893547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
    Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
    Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.